Metraipolis › archive › dc_ddc1a46308fe
Safety and preliminary efficacy of Disitamab Vedotin combined with Toripalimab and concurrent radiotherapy in bladder-preserving treatment for HER2-positive… — Europe PMC PMID:42459305
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42459305
- DOI
- 10.3389/fonc.2026.1880457
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-18T14:03:24.739Z
- SHA-256 of the archived text
1060453fec5b160b55710f1204581c447588049a7326a871bb4336019a07fa14- Stable URL of this page
https://metraipolis.com/documento/dc_ddc1a46308fe
How to cite
Safety and preliminary efficacy of Disitamab Vedotin combined with Toripalimab and concurrent radiotherapy in bladder-preserving treatment for HER2-positive… — Europe PMC PMID:42459305 — Europe PMC (en), https://europepmc.org/article/MED/42459305 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ddc1a46308fe (Metraipolis archive dc_ddc1a46308fe, sha256 1060453fec5b160b55710f1204581c447588049a7326a871bb4336019a07fa14)
BibTeX
@misc{dcddc1a46308fe,
title = {Safety and preliminary efficacy of Disitamab Vedotin combined with Toripalimab and concurrent radiotherapy in bladder-preserving treatment for HER2-positive… — Europe PMC PMID:42459305},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42459305},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ddc1a46308fe; sha256 1060453fec5b160b55710f1204581c447588049a7326a871bb4336019a07fa14},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42459305. Agents can read the archived copy with the MCP tool read_document.